Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

205 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia.
Frangoul H, Altshuler D, Cappellini MD, Chen YS, Domm J, Eustace BK, Foell J, de la Fuente J, Grupp S, Handgretinger R, Ho TW, Kattamis A, Kernytsky A, Lekstrom-Himes J, Li AM, Locatelli F, Mapara MY, de Montalembert M, Rondelli D, Sharma A, Sheth S, Soni S, Steinberg MH, Wall D, Yen A, Corbacioglu S. Frangoul H, et al. Among authors: corbacioglu s. N Engl J Med. 2021 Jan 21;384(3):252-260. doi: 10.1056/NEJMoa2031054. Epub 2020 Dec 5. N Engl J Med. 2021. PMID: 33283989 Clinical Trial.
Haploidentical stem cell transplantation with CD3+-/CD19+- depleted peripheral stem cells for patients with advanced stage sickle cell disease and no alternative donor: results of a pilot study.
Foell J, Pfirstinger B, Rehe K, Wolff D, Holler E, Corbacioglu S. Foell J, et al. Among authors: corbacioglu s. Bone Marrow Transplant. 2017 Jun;52(6):938-940. doi: 10.1038/bmt.2017.49. Epub 2017 Apr 24. Bone Marrow Transplant. 2017. PMID: 28436975 Clinical Trial. No abstract available.
Risk factors and outcomes according to age at transplantation with an HLA-identical sibling for sickle cell disease.
Cappelli B, Volt F, Tozatto-Maio K, Scigliuolo GM, Ferster A, Dupont S, Simões BP, Al-Seraihy A, Aljurf MD, Almohareb F, Belendez C, Matthes S, Dhedin N, Pondarre C, Dalle JH, Bertrand Y, Vannier JP, Kuentz M, Lutz P, Michel G, Rafii H, Neven B, Zecca M, Bader P, Cavazzana M, Labopin M, Locatelli F, Magnani A, Ruggeri A, Rocha V, Bernaudin F, de La Fuente J, Corbacioglu S, Gluckman E; Eurocord, the Cellular Therapy and Immunobiology Working Party (CTIWP) and the Paediatric Diseases Working Party (PDWP) of the EBMT. Cappelli B, et al. Among authors: corbacioglu s. Haematologica. 2019 Dec;104(12):e543-e546. doi: 10.3324/haematol.2019.216788. Epub 2019 Apr 24. Haematologica. 2019. PMID: 31018975 Free PMC article. No abstract available.
Haploidentical CD3 or α/β T-cell depleted HSCT in advanced stage sickle cell disease.
Foell J, Schulte JH, Pfirstinger B, Troeger A, Wolff D, Edinger M, Hofmann P, Aslanidis C, Lang P, Holler E, Eggert A, Corbacioglu S. Foell J, et al. Among authors: corbacioglu s. Bone Marrow Transplant. 2019 Nov;54(11):1859-1867. doi: 10.1038/s41409-019-0550-0. Epub 2019 May 14. Bone Marrow Transplant. 2019. PMID: 31089288
Proceedings of the meeting of the Pediatric Disease Working Party (PDWP) of the European group for Blood and Marrow Transplantation (EBMT) on sickle cell disease 16-17 May 2019, Regensburg, Germany.
Corbacioglu S, Gluckman E, Alahmari A, Kassim A, de la Fuente J. Corbacioglu S, et al. Hematol Oncol Stem Cell Ther. 2020 Jun;13(2):51-52. doi: 10.1016/j.hemonc.2019.12.001. Epub 2020 Mar 12. Hematol Oncol Stem Cell Ther. 2020. PMID: 32202247 Free article. No abstract available.
The role of haematopoietic stem cell transplantation for sickle cell disease in the era of targeted disease-modifying therapies and gene editing.
de la Fuente J, Gluckman E, Makani J, Telfer P, Faulkner L, Corbacioglu S; Paediatric Diseases Working Party of the European Society for Blood and Marrow Transplantation. de la Fuente J, et al. Among authors: corbacioglu s. Lancet Haematol. 2020 Dec;7(12):e902-e911. doi: 10.1016/S2352-3026(20)30283-0. Lancet Haematol. 2020. PMID: 33242447 Review.
205 results